EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection

International Journal of Cancer

Volumn 136, Issue 12, 2015, Pages 2752-2760

  Giuliano, Anna R ^a   Nyitray, Alan G ^b   Kreimer, Aimée R ^c   Pierce Campbell, Christine M ^a   Goodman, Marc T ^d   Sudenga, Staci L ^a   Monsonego, Joseph ^e   Franceschi, Silvia ^f  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e Institute of the Cervix   (France)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

cancer; epidemiology; gender differences; human papillomavirus; natural history

Indexed keywords

ANUS DISEASE; ARTICLE; CANCER INCIDENCE; DISEASE ASSOCIATION; DISEASE TRANSMISSION; GENDER; GENITAL TRACT INFECTION; HETEROSEXUALITY; HUMAN; INFECTION RATE; INFECTION RISK; INFECTION SENSITIVITY; MOUTH INFECTION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEROLOGY; SEROPREVALENCE; FEMALE; INCIDENCE; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; PHYSIOLOGY; SEX DIFFERENCE; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

FEMALE; HUMANS; INCIDENCE; MALE; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PENILE NEOPLASMS; SEX FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84927571505     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29082     Document Type: Article

References (105)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum 2007; 90: 1-636.
2. Markowitz LE, Hariri S, Lin C, et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013; 208: 385-93.
3. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012; 206: 1645-51.
4. Baldur-Felskov B, Dehlendorff C, Munk C, et al. Early impact of human papillomavirus vaccination on cervical neoplasia-nationwide follow-up of young Danish women. J Natl Cancer Inst 2014; 106: djt460.
5. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011; 377: 2085-92.
6. Powell SE, Hariri S, Steinau M, et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012; 31: 109-13.
7. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. Br Med J 2013; 346: f2032.
8. Bauer HM, Wright G, Chow J,. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010. Am J Public Health 2012; 102: 833-5.
9. Arbyn M, de Sanjose S, Saraiya M, et al. EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease. Int J Cancer 2012; 131: 1969-82.
10. Gillison ML, Castellsague X, Chaturvedi A, et al. Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer 2014; 134: 497-507.
11. de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13: 607-15.
12. Franceschi S, Vignat J, de Martel C,. Comparison of HPV-related disease in men and women. EUROGIN International Congress, Florence, Italy, 2013.
13. Combes JD, Franceschi S,. Role of human papillomavirus in non-oropharyngeal head and neck cancers. Oral Oncol 2014; 50: 370-9.
14. Giuliano AR, Lazcano-Ponce E, Villa LL, et al. The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008; 17: 2036-43.
15. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. Jr Am Med Assoc 2007; 297: 813-9.
16. Herrero R, Castle PE, Schiffman M, et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796-807.
17. Giuliano AR, Nielson CM, Flores R, et al. The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis 2007; 196: 1146-52.
18. Barzon L, Militello V, Pagni S, et al. Distribution of human papillomavirus types in the anogenital tract of females and males. J Med Virol 2010; 82: 1424-30.
19. Giuliano AR, Lee JH, Fulp W, et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011; 377: 932-40.
20. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1808-16.
21. Muñoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004; 190: 2077-87.
22. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection. J Natl Cancer Inst 2010; 102: 315-24.
23. Chaturvedi AK,. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health 2010; 46: S20-6.
24. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13: 487-500.
25. Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Diseases 2012; 54: 1026-34.
26. Alvarez-Arguelles ME, Melon S, Junquera ML, et al. Human papillomavirus infection in a male population attending a sexually transmitted infection service. PLoS One 2013; 8: e54375.
27. Chin-Hong PV, Vittinghoff E, Cranston RD, et al. Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis 2004; 190: 2070-6.
28. Dona MG, Palamara G, Di Carlo A, et al. Prevalence, genotype diversity and determinants of anal HPV infection in HIV-uninfected men having sex with men. J Clin Virol 2012; 54: 185-9.
29. Gao L, Zhou F, Li X, et al. Anal HPV infection in HIV-positive men who have sex with men from China. PLoS One 2010; 5: e15256.
30. Hu Y, Qian HZ, Sun J, et al. Anal human papillomavirus infection among HIV-infected and uninfected men who have sex with men in Beijing, China. J Acquir Immune Defic Syndr (1999) 2013; 64: 103-14.
31. Kiviat NB, Critchlow CW, Holmes KK, et al. Association of anal dysplasia and human papillomavirus with immunosuppression and HIV infection among homosexual men. AIDS 1993; 7: 43-9.
32. Nyitray A, Nielson CM, Harris RB, et al. Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis 2008; 197: 1676-84.
33. Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365: 1576-85.
34. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177: 361-7.
35. Phanuphak N, Teeratakulpisarn N, Pankam T, et al. Anal human papillomavirus infection among Thai men who have sex with men with and without HIV infection: prevalence, incidence, and persistence. J Acquir Immune Defic Syndr (1999) 2013; 63: 472-9.
36. Vajdic CM, van Leeuwen MT, Jin F, et al. Anal human papillomavirus genotype diversity and co-infection in a community-based sample of homosexual men. Sex Transm Infect 2009; 85: 330-5.
37. Castro FA, Quint W, Gonzalez P, et al. Prevalence of and risk factors for anal human papillomavirus infection among young healthy women in Costa Rica. J Infect Dis 2012; 206: 1103-10.
38. Hernandez BY, Ka'opua LS, Scanlan L, et al. Cervical and anal human papillomavirus infection in adult women in American Samoa. Asia Pac J Public Health 2013; 25: 19-31.
39. Hernandez BY, McDuffie K, Zhu X, et al. Anal human papillomavirus infection in women and its relationship with cervical infection. Cancer Epidemiol Biomarkers Prev 2005; 14: 2550-6.
40. Hessol NA, Holly EA, Efird JT, et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009; 23: 59-70.
41. Pierangeli A, Scagnolari C, Selvaggi C, et al. High detection rate of human papillomavirus in anal brushings from women attending a proctology clinic. J Infect 2012; 65: 255-61.
42. Schlecht NF, Burk RD, Nucci-Sack A, et al. Cervical, anal and oral HPV in an adolescent inner-city health clinic providing free vaccinations. PLoS One 2012; 7: e37419.
43. dos Ramos Farias MS, Picconi MA, Garcia MN, et al. Human papilloma virus genotype diversity of anal infection among trans (male to female transvestites, transsexuals or transgender) sex workers in Argentina. J Clin Virol 2011; 51: 96-9.
44. Nyitray AG,. Comparing and contrasting the natural history of anal HPV among women and men. EUROGIN International Congress, Florence, Italy, 2013.
45. Hessol NA, Holly EA, Efird JT, et al. Concomitant anal and cervical human papillomavirusV infections and intraepithelial neoplasia in HIV-infected and uninfected women. AIDS 2013; 27: 1743-51.
46. Xi LF, Critchlow CW, Wheeler CM, et al. Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Res 1998; 58: 3839-44.
47. Nyitray AG, Carvalho, da Silva RJ, Baggio ML, et al. Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis 2011; 203: 49-57.
48. Critchlow CW, Hawes SE, Kuypers JM, et al. Effect of HIV infection on the natural history of anal human papillomavirus infection. AIDS 1998; 12: 1177-84.
49. Pierangeli A, Scagnolari C, Degener AM, et al. Type-specific human papillomavirus-DNA load in anal infection in HIV-positive men. AIDS 2008; 22: 1929-35.
50. Donà MG, Palamara G, Di Carlo A, et al. Prevalence, genotype diversity and determinants of anal HPV infection in HIV-uninfected men having sex with men. J Clin Virol 2012; 54: 185-9.
51. Dona MG, Benevolo M, Vocaturo A, et al. Anal cytological abnormalities and epidemiological correlates among men who have sex with men at risk for HIV-1 infection. BMC Cancer 2012; 12: 476.
52. Hernandez BY, Ka'opua LS, Scanlan L, et al. Cervical and anal human papillomavirus infection in adult women in American Samoa. Asia Pac J Public Health 2012.
53. Nyitray AG, Smith D, Villa L, et al. Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross-national study. J Infect Dis 2010; 201: 1498-508.
54. Crawford R, Grignon AL, Kitson S, et al. High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology. BMC Cancer 2011; 11: 473.
55. Hillemanns P, Ellerbrock TV, McPhillips S, et al. Prevalence of anal human papillomavirus infection and anal cytologic abnormalities in HIV-seropositive women. AIDS 1996; 10: 1641-7.
56. Moscicki AB, Durako SJ, Houser J, et al. Human papillomavirus infection and abnormal cytology of the anus in HIV-infected and uninfected adolescents. AIDS 2003; 17: 311-20.
57. Palefsky JM, Holly EA, Ralston ML, et al. Prevalence and risk factors for anal human papillomavirus infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183: 383-91.
58. Valari O, Koliopoulos G, Karakitsos P, et al. Human papillomavirus DNA and mRNA positivity of the anal canal in women with lower genital tract HPV lesions: predictors and clinical implications. Gynecol Oncol 2011; 122: 505-8.
59. Hernandez BY, Wilkens LR, Zhu X, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis 2008; 14: 888-94.
60. Goodman MT, Shvetsov YB, McDuffie K, et al. Acquisition of anal human papillomavirus (HPV) infection in women: the Hawaii HPV Cohort study. J Infect Dis 2008; 197: 957-66.
61. Shvetsov YB, Hernandez BY, McDuffie K, et al. Duration and clearance of anal human papillomavirus (HPV) infection among women: the Hawaii HPV cohort study. Clin Infect Dis 2009; 48: 536-46.
62. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al. Six-month incidence, persistence, and factors associated with persistence of anal human papillomavirus in men: the HPV in men study. J Infect Dis 2011; 204: 1711-22.
63. Chin-Hong PV, Husnik M, Benet DJ, et al. High incidence and persistence of anal human papillomavirus infection among HIV-negative sexually active men who have sex with men: The EXPLORE Study. 24th International Papillomavirus Conference, Beijing, China, 2007.
64. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 2009-2010. Jr Am Med Assoc 2012; 307: 693-703.
65. Kreimer AR, Bhatia RK, Messeguer AL, et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis 2010; 37: 386-91.
66. de Sanjose S, Diaz M, Castellsague X, et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007; 7: 453-9.
67. Beachler DC, D'Souza G, Sugar EA, et al. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 2013; 208: 330-9.
68. Edelstein ZR, Schwartz SM, Hawes S, et al. Rates and determinants of oral human papillomavirus infection in young men. Sex Transm Dis 2012; 39: 860-7.
69. Kero K, Rautava J, Syrjanen K, et al. Smoking increases oral HPV persistence among men: 7-year follow-up study. Eur J Clin Microbiol Infect Dis 2014; 33: 123-33.
70. Kreimer AR, Pierce Campbell CM, Lin HY, et al. Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet 2013; 382: 877-87.
71. Pickard RK, Xiao W, Broutian TR, et al. The prevalence and incidence of oral human papillomavirus infection among young men and women, aged 18-30 years. Sex Transm Dis 2012; 39: 559-66.
72. Rintala M, Grenman S, Puranen M, et al. Natural history of oral papillomavirus infections in spouses: a prospective Finnish HPV Family Study. J Clin Virol 2006; 35: 89-94.
73. Videla S, Darwich L, Canadas MP, et al. Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis 2013; 40: 3-10.
74. Kreimer AR, Villa A, Nyitray AG, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev 2011; 20: 172-82.
75. Pierce Campbell CM, Kreimer AR, O'Keefe MT, et al. Oral HPV16 persistence among participants of the HPV Infeciton in Men (HIM) Study. EUROGIN International Congress, Florence, Italy, 2013.
76. Safaeian M, Porras C, Schiffman M, et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-infections. J Natl Cancer Inst 2010; 102: 1653-62.
77. Lu B, Viscidi RP, Wu Y, et al. Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res 2012; 72: 676-85.
78. Carter JJ, Koutsky LA, Hughes JP, et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-9.
79. Lu B, Viscidi RP, Villa LL, et al. Capsid antibody response to genital HPV 6, 11, 16, and 18 infection in healthy men. 28th International Papillomavirus Conference, San Juan, Puerto Rico, 2012.
80. Scherpenisse M, Schepp RM, Mollers M, et al. Comparison of different assays to assess human papillomavirus (HPV) type 16- and 18-specific antibodies after HPV infection and vaccination. Clin Vaccine Immunol 2013; 20: 1329-32.
81. Desai S, Chapman R, Jit M, et al. Prevalence of human papillomavirus antibodies in males and females in England. Sex Transm Dis 2011; 38: 622-9.
82. Heiligenberg M, Michael KM, Kramer MA, et al. Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam. Sex Transm Dis 2010; 37: 672-80.
83. Kreimer AR, Alberg AJ, Viscidi R, et al. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 2004; 31: 247-56.
84. Markowitz LE, Sternberg M, Dunne EF, et al. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009; 200: 1059-67.
85. Newall AT, Brotherton JM, Quinn HE, et al. Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 2008; 46: 1647-55.
86. Slavinsky J, 3rd, Kissinger P, Burger L, et al. Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS 2001; 12: 516-23.
87. Stone KM, Karem KL, Sternberg MR, et al. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002; 186: 1396-402.
88. Svare EI, Kjaer SK, Nonnenmacher B, et al. Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis 1997; 176: 876-83.
89. Thompson DL, Douglas JM, Jr, Foster M, et al. Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis 2004; 190: 1563-74.
90. Plitt SS, Sherman SG, Viscidi RP, et al. Human papillomavirus seroprevalence among young male and female drug users. Sex Transm Dis 2007; 34: 676-80.
91. Hariri S, Dunne EF, Sternberg M, et al. Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health And Nutrition Examination Survey, 1991-1994. Sex Transm Dis 2008; 35: 298-303.
92. Carter JJ, Koutsky LA, Wipf GC, et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996; 174: 927-36.
93. Edelstein ZR, Carter JJ, Garg R, et al. Serum antibody response following genital {alpha}9 human papillomavirus infection in young men. J Infect Dis 2011; 204: 209-16.
94. Carter JJ, Madeleine MM, Shera K, et al. Human papillomavirus 16 and 18 L1 serology compared across anogenital cancer sites. Cancer Res 2001; 61: 1934-40.
95. Ho GY, Studentsov Y, Hall CB, et al. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 2002; 186: 737-42.
96. Viscidi RP, Schiffman M, Hildesheim A, et al. Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 2004; 13: 324-7.
97. Veldhuijzen NJ, Snijders PJ, Reiss P, et al. Factors affecting transmission of mucosal human papillomavirus. Lancet Infect Dis 2010; 10: 862-74.
98. Reiter PL, Pendergraft WF, 3rd, Brewer NT,. Meta-analysis of human papillomavirus infection concordance. Cancer Epidemiol Biomarkers Prev 2010; 19: 2916-31.
99. Burchell AN, Coutlee F, Tellier PP, et al. Genital transmission of human papillomavirus in recently formed heterosexual couples. J Infect Dis 2011; 204: 1723-9.
100. Mbulawa ZZ, Johnson LF, Marais DJ, et al. The impact of human immunodeficiency virus on human papillomavirus transmission in heterosexually active couples. J Infect 2013; 67: 51-8.
101. Nyitray AG, Lin HY, Fulp WJ, et al. The role of monogamy and duration of heterosexual relationships in human papillomavirus transmission. J Infect Dis 2014; 209: 1007-15.
102. Widdice L, Ma Y, Jonte J, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis 2013; 207: 1286-94.
103. Moscicki AB, Schiffman M, Burchell A, et al. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine 2012; 30: F24-33.
104. Winer RL, Hughes JP, Feng Q, et al. Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev 2010; 19: 1682-5.
105. Goodman MT, Shvetsov YB, McDuffie K, et al. Sequential acquisition of human papillomavirus (HPV) infection of the anus and cervix: the Hawaii HPV Cohort Study. J Infect Dis 2010; 201: 1331-9.